Non-viral, non-lipid nanoparticles offer versatile RNA delivery platforms beyond LNPs for diverse therapeutic applications
Background
While RNA therapeutics hold immense promise for gene modulation and protein expression in areas like vaccination, oncology, and genetic disorders, their clinical translation is hampered by inefficient delivery, insufficient tissue specificity, and long-term safety concerns. Current lipid nanoparticle (LNP) formulations, though clinically validated for vaccines, often lack the versatility needed for broader therapeutic applications, necessitating novel delivery systems.
Study Design
This comprehensive review systematically examined non-viral and non-lipid RNA nanocarriers, outlining cargo-specific delivery requirements for various RNA modalities. It analyzed polymeric nanoparticles, inorganic nanomaterials, and peptide- and protein-based carriers, alongside virus-like particles, as distinct strategies to overcome extracellular, tissue-level, cellular, and intracellular barriers. The authors evaluated cross-platform trade-offs based on RNA association and release, cargo compatibility, administration route, biodegradability, immune interactions, and manufacturability, using clinically validated lipid nanoparticle (LNP) formulations as translational benchmarks.
Results
The review concluded that non-viral and non-lipid nanocarriers offer complementary platforms for context-specific RNA therapy, addressing limitations of current LNP systems. These alternative carriers demonstrate potential for enhanced tissue targeting, improved intracellular bioavailability, and reduced long-term safety concerns.
Polymeric nanoparticles, inorganic nanomaterials, and peptide- and protein-based carriers show promise in overcoming specific delivery barriers, influencing biodistribution and intracellular RNA activity. Evaluations highlighted their varying strengths in
RNA association and release,cargo compatibility, andrepeat-dose compatibility. While LNPs remain the most clinically advanced, non-lipid systems are being developed for productive delivery, release efficiency, and improved material fate, broadening the scope of RNA therapeutics beyond vaccinology to oncology, genetic disorders, and inflammatory diseases.
Key Findings
- Non-viral and non-lipid nanocarriers are emerging as complementary platforms for RNA therapy.
- These alternative carriers address limitations of LNPs, offering enhanced tissue specificity and reduced immunogenicity.
- Polymeric, inorganic, and peptide/protein-based nanoparticles show distinct advantages in overcoming delivery barriers.
- Carrier architecture significantly influences biodistribution, intracellular RNA activity, and therapeutic efficacy.
- New platforms aim for improved
repeat-dose compatibilityand long-term material fate for broader clinical use.
Why It Matters
This review significantly broadens the perspective on RNA therapeutic delivery, moving beyond the current LNP paradigm. For researchers and biohackers exploring advanced gene modulation, it highlights that diverse non-viral and non-lipid platforms could enable more precise tissue targeting and reduced systemic side effects. Developing context-specific nanocarriers could unlock new therapeutic avenues for diseases currently underserved by existing delivery methods. While these systems are largely preclinical, this work underscores the need for continued innovation in material science to translate these promising platforms into clinically viable protocols, potentially allowing for safer and more effective repeat dosing.
rna
nanocarriers
drug-delivery
non-viral
non-lipid
gene-therapy